| Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease W Afif, EV Loftus Jr, WA Faubion, SV Kane, DH Bruining, KA Hanson, ... Official journal of the American College of Gastroenterology| ACG 105 (5 …, 2010 | 607 | 2010 |
| Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus B Bressler, JK Marshall, CN Bernstein, A Bitton, J Jones, GI Leontiadis, ... Gastroenterology 148 (5), 1035-1058. e3, 2015 | 442 | 2015 |
| Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease R Battat, U Kopylov, T Bessissow, A Bitton, A Cohen, A Jain, M Martel, ... Clinical Gastroenterology and Hepatology 15 (9), 1427-1434. e2, 2017 | 229 | 2017 |
| Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab W Afif, JA Leighton, SB Hanauer, EV Loftus Jr, WA Faubion, DS Pardi, ... Inflammatory bowel diseases 15 (9), 1302-1307, 2009 | 163 | 2009 |
| Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—the McGill experience U Kopylov, W Afif, A Cohen, A Bitton, G Wild, T Bessissow, J Wyse, ... Journal of Crohn's and Colitis 8 (11), 1516-1522, 2014 | 155 | 2014 |
| The Modified Mayo Endoscopic Score (MMES): a new index for the assessment of extension and severity of endoscopic activity in ulcerative colitis patients T Lobatón, T Bessissow, G De Hertogh, B Lemmens, C Maedler, ... Journal of Crohn's and Colitis 9 (10), 846-852, 2015 | 146 | 2015 |
| a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease R Khanna, BD Sattin, W Afif, EI Benchimol, EJ Bernard, A Bitton, ... Alimentary pharmacology & therapeutics 38 (5), 447-459, 2013 | 136 | 2013 |
| Small bowel capsule endoscopy in the management of established Crohn's disease: clinical impact, safety, and correlation with inflammatory biomarkers U Kopylov, A Nemeth, A Koulaouzidis, R Makins, G Wild, W Afif, A Bitton, ... Inflammatory Bowel Diseases 21 (1), 93-100, 2015 | 126 | 2015 |
| Compliance with methicillin-resistant Staphylococcus aureus precautions in a teaching hospital W Afif, P Huor, P Brassard, VG Loo American journal of infection control 30 (7), 430-433, 2002 | 123 | 2002 |
| Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease T Bessissow, NH Le, K Rollet, W Afif, A Bitton, G Sebastiani Inflammatory bowel diseases 22 (8), 1937-1944, 2016 | 120 | 2016 |
| A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease AS Cheifetz, MT Abreu, W Afif, RK Cross, MC Dubinsky, EV Loftus Jr, ... Official journal of the American College of Gastroenterology| ACG 116 (10 …, 2021 | 117 | 2021 |
| Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis U Kopylov, T Al-Taweel, M Yaghoobi, B Nauche, A Bitton, PL Lakatos, ... Journal of Crohn's and Colitis 8 (12), 1632-1641, 2014 | 108 | 2014 |
| Clinical practice guideline for the medical management of perianal fistulizing Crohn’s disease: the Toronto consensus AH Steinhart, R Panaccione, L Targownik, B Bressler, R Khanna, ... Inflammatory bowel diseases 25 (1), 1-13, 2019 | 105 | 2019 |
| Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study U Kopylov, M Vutcovici, A Kezouh, E Seidman, A Bitton, W Afif Inflammatory bowel diseases 21 (8), 1847-1853, 2015 | 96 | 2015 |
| Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases: a cohort study using transient elastography C Saroli Palumbo, S Restellini, CY Chao, A Aruljothy, C Lemieux, G Wild, ... Inflammatory bowel diseases 25 (1), 124-133, 2019 | 90 | 2019 |
| Canadian Association of Gastroenterology clinical practice guideline for the management of luminal Crohn’s disease R Panaccione, AH Steinhart, B Bressler, R Khanna, JK Marshall, ... Journal of the Canadian Association of Gastroenterology 2 (3), e1-e34, 2019 | 77 | 2019 |
| Development and validation of a test to monitor endoscopic activity in patients with Crohn’s disease based on serum levels of proteins G D’Haens, O Kelly, R Battat, MS Silverberg, D Laharie, E Louis, ... Gastroenterology 158 (3), 515-526. e10, 2020 | 76 | 2020 |
| Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives K Papamichael, W Afif, D Drobne, MC Dubinsky, M Ferrante, PM Irving, ... The lancet Gastroenterology & hepatology 7 (2), 171-185, 2022 | 64 | 2022 |
| Defining quality indicators for best-practice management of inflammatory bowel disease in Canada GC Nguyen, SM Devlin, W Afif, B Bressler, SE Gruchy, GG Kaplan, ... Canadian Journal of Gastroenterology and Hepatology 28, 275-285, 2014 | 62 | 2014 |
| Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy U Kopylov, J Hanzel, C Liefferinckx, D De Marco, N Imperatore, N Plevris, ... Alimentary pharmacology & therapeutics 52 (1), 135-142, 2020 | 59 | 2020 |
